KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
Canada - TSX:GUD - CA4990531069 - Common Stock
6.05 CAD
-0.02 (-0.33%)
We assign a fundamental rating of 5 out of 10 to GUD. GUD was compared to 31 industry peers in the Pharmaceuticals industry. The financial health of GUD is average, but there are quite some concerns on its profitability. GUD shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year GUD has reported negative net income.
In the past year GUD had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: GUD reported negative net income in multiple years.
GUD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of GUD (0.04%) is better than 61.29% of its industry peers.
With a decent Return On Equity value of 0.05%, GUD is doing good in the industry, outperforming 64.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.04% | ||
| ROE | 0.05% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 0.10%, GUD is in the better half of the industry, outperforming 61.29% of the companies in the same industry.
In the last couple of years the Profit Margin of GUD has declined.
With a Gross Margin value of 42.92%, GUD perfoms like the industry average, outperforming 58.06% of the companies in the same industry.
In the last couple of years the Gross Margin of GUD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 0.1% | ||
| GM | 42.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GUD has less shares outstanding
Compared to 5 years ago, GUD has less shares outstanding
The debt/assets ratio for GUD has been reduced compared to a year ago.
2.2 Solvency
GUD has an Altman-Z score of 2.11. This is not the best score and indicates that GUD is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.11, GUD belongs to the top of the industry, outperforming 87.10% of the companies in the same industry.
GUD has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GUD (0.11) is better than 64.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.11 |
ROIC/WACCN/A
WACC8.37%
2.3 Liquidity
A Current Ratio of 2.47 indicates that GUD has no problem at all paying its short term obligations.
The Current ratio of GUD (2.47) is better than 64.52% of its industry peers.
GUD has a Quick Ratio of 1.50. This is a normal value and indicates that GUD is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.50, GUD is doing good in the industry, outperforming 64.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.5 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 100.00% over the past year.
The earnings per share for GUD have been decreasing by -13.46% on average. This is quite bad
Looking at the last year, GUD shows a quite strong growth in Revenue. The Revenue has grown by 13.82% in the last year.
Measured over the past years, GUD shows a very strong growth in Revenue. The Revenue has been growing by 50.87% on average per year.
EPS 1Y (TTM)100%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-550%
Revenue 1Y (TTM)13.82%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%12.33%
3.2 Future
The Earnings Per Share is expected to grow by 54.05% on average over the next years. This is a very strong growth
Based on estimates for the next years, GUD will show a quite strong growth in Revenue. The Revenue will grow by 10.10% on average per year.
EPS Next Y-330.28%
EPS Next 2Y10.09%
EPS Next 3Y50.87%
EPS Next 5Y54.05%
Revenue Next Year14.81%
Revenue Next 2Y12.31%
Revenue Next 3Y8.59%
Revenue Next 5Y10.1%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Forward Earnings ratio of 99.83, the valuation of GUD can be described as expensive.
67.74% of the companies in the same industry are more expensive than GUD, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 32.73. GUD is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 99.83 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GUD is valued a bit cheaper than 61.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 13.3 |
4.3 Compensation for Growth
A more expensive valuation may be justified as GUD's earnings are expected to grow with 50.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.09%
EPS Next 3Y50.87%
5. Dividend
5.1 Amount
No dividends for GUD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:GUD (11/7/2025, 7:00:00 PM)
6.05
-0.02 (-0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.23%
Inst Owner ChangeN/A
Ins Owners1.86%
Ins Owner ChangeN/A
Market Cap603.06M
Revenue(TTM)384.56M
Net Income(TTM)383.00K
Analysts78.18
Price Target7.96 (31.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-224.57%
Min EPS beat(2)-815.07%
Max EPS beat(2)365.93%
EPS beat(4)2
Avg EPS beat(4)-21.94%
Min EPS beat(4)-815.07%
Max EPS beat(4)461.4%
EPS beat(8)3
Avg EPS beat(8)-230%
EPS beat(12)6
Avg EPS beat(12)-123.05%
EPS beat(16)7
Avg EPS beat(16)-384.28%
Revenue beat(2)2
Avg Revenue beat(2)5.97%
Min Revenue beat(2)0.88%
Max Revenue beat(2)11.06%
Revenue beat(4)4
Avg Revenue beat(4)5.89%
Min Revenue beat(4)0.88%
Max Revenue beat(4)11.06%
Revenue beat(8)7
Avg Revenue beat(8)5%
Revenue beat(12)11
Avg Revenue beat(12)8.91%
Revenue beat(16)14
Avg Revenue beat(16)9.42%
PT rev (1m)0%
PT rev (3m)3.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-110.42%
EPS NY rev (1m)0%
EPS NY rev (3m)-302.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 99.83 | ||
| P/S | 1.57 | ||
| P/FCF | N/A | ||
| P/OCF | 19.83 | ||
| P/B | 0.79 | ||
| P/tB | 2.09 | ||
| EV/EBITDA | 13.3 |
EPS(TTM)0
EYN/A
EPS(NY)0.06
Fwd EY1%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.31
OCFY5.04%
SpS3.86
BVpS7.66
TBVpS2.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.04% | ||
| ROE | 0.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 0.1% | ||
| GM | 42.92% | ||
| FCFM | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score6
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.96 | ||
| Cap/Depr | 62.43% | ||
| Cap/Sales | 8.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 72.19% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.5 | ||
| Altman-Z | 2.11 |
F-Score6
WACC8.37%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-550%
EPS Next Y-330.28%
EPS Next 2Y10.09%
EPS Next 3Y50.87%
EPS Next 5Y54.05%
Revenue 1Y (TTM)13.82%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%12.33%
Revenue Next Year14.81%
Revenue Next 2Y12.31%
Revenue Next 3Y8.59%
Revenue Next 5Y10.1%
EBIT growth 1Y-652.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year397.68%
EBIT Next 3Y80.27%
EBIT Next 5Y54.06%
FCF growth 1Y-140.33%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y60.79%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you provide the ChartMill fundamental rating for KNIGHT THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to GUD.CA.
Can you provide the valuation status for KNIGHT THERAPEUTICS INC?
ChartMill assigns a valuation rating of 2 / 10 to KNIGHT THERAPEUTICS INC (GUD.CA). This can be considered as Overvalued.
What is the profitability of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) has a profitability rating of 3 / 10.
What is the financial health of KNIGHT THERAPEUTICS INC (GUD.CA) stock?
The financial health rating of KNIGHT THERAPEUTICS INC (GUD.CA) is 6 / 10.
Can you provide the expected EPS growth for GUD stock?
The Earnings per Share (EPS) of KNIGHT THERAPEUTICS INC (GUD.CA) is expected to decline by -330.28% in the next year.